← All trials
NCT06819774
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Feb 11, 2025
- Last posted
- Feb 11, 2025
- Enrollment
- 284
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong New Time Pharmaceutical Co., LTDLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.